Source: Tengion, Inc.
Date: January 5, 2007
Summary:
Tengion, Inc., a biotechnology company in the field of adult stem cell research for developing organs and tissues using a patient's own cells, announced it has initiated a Phase II multi-center clinical study for its urinary neo-bladder construct. The study is being conducted in pediatric patients with spina bifida who have failing bladders that predispose them to a risk of kidney failure and incontinence even when they receive optimal medical therapy.
No comments:
Post a Comment